International
The Morning Science

What science found today

‹
 

Launch

Next-Generation Oral SERD Approved for Breast Cancer

MedPage Today ·

Next-Generation Oral SERD Approved for Breast Cancer

The Brief

  • The FDA approved giredestrant (brand name Wilserdly) in combination with everolimus.
  • The approval covers previously treated ER-positive, HER2-negative, ESR1-mutated breast cancer.
  • Giredestrant is described as a next-generation oral selective estrogen receptor degrader (SERD).

Why it matters

It adds an oral treatment option for a subset of previously treated, ESR1-mutated, ER-positive breast cancer, which matters for oncologists choosing second-line therapy.

Who’s affected

  • physicians treating ER-positive, HER2-negative breast cancer
  • patients with ESR1-mutated advanced breast cancer

(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...

Timeline

  1. FDA approves giredestrant (Wilserdly) with everolimus

  2. MedPageToday.com - medical news for physicians

    Next-Generation Oral SERD Approved for Breast Cancer

How do you feel about this?

0 Comments

    Next-Generation Oral SERD Approved for Breast Cancer – The Morning Science